NCT00474006View on ClinicalTrials.gov

High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

PHASE3CompletedINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

August 31, 2008

Study Completion Date

April 30, 2010

Conditions
ACUTE MYELOGENOUS LEUKEMIA
Interventions
DRUG

arm II

Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days

Trial Locations (1)

138-736

Asan Medical Center, Seoul

All Listed Sponsors
lead

Cooperative Study Group A for Hematology

NETWORK

NCT00474006 - High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML | Biotech Hunter | Biotech Hunter